Skip to Content
Merck
  • Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer.

Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer.

EMBO molecular medicine (2019-10-28)
Liping Ye, Chuyong Lin, Xi Wang, Qiji Li, Yue Li, Meng Wang, Zekun Zhao, Xianqiu Wu, Dongni Shi, Yunyun Xiao, Liangliang Ren, Yunting Jian, Meisongzhu Yang, Ruizhang Ou, Guangzheng Deng, Ying Ouyang, Xiangfu Chen, Jun Li, Libing Song
ABSTRACT

Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor-alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains elusive. Herein, we reported that Spalt-like transcription factor 2 (SALL2) expression was significantly reduced during tamoxifen therapy through transcription profiling analysis of 9 paired primary pre-tamoxifen-treated and relapsed tamoxifen-resistant breast cancer tissues. SALL2 transcriptionally upregulated ESR1 and PTEN through directly binding to the DNA promoters. By contrast, silencing SALL2 induced downregulation of ERα and PTEN and activated the Akt/mTOR signaling, resulting in estrogen-independent growth and tamoxifen resistance in ERα-positive breast cancer. Furthermore, hypermethylation of SALL2 promoter was found in tamoxifen-resistant breast cancer. Importantly, in vivo experiments showed that DNA methyltransferase inhibitor-mediated SALL2 restoration resensitized tamoxifen-resistant breast cancer to tamoxifen therapy. These findings shed light on the mechanism of SALL2 in regulation of ER and represent a potential clinical signature that can be used to categorize breast cancer patients who may benefit from co-therapy with tamoxifen and DNMT inhibitor.

MATERIALS
Product Number
Brand
Product Description

Roche
Cell Proliferation Kit I (MTT)
Pricing and availability is not currently available.
Sigma-Aldrich
LookOut® Mycoplasma PCR Detection Kit, Optimized for use with JumpStart Taq DNA Polymerase, D9307.
Pricing and availability is not currently available.
Sigma-Aldrich
β-Estradiol, BioReagent, powder, suitable for cell culture
Pricing and availability is not currently available.
Sigma-Aldrich
Doxycycline hyclate
Pricing and availability is not currently available.
Sigma-Aldrich
Anti-SALL2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Pricing and availability is not currently available.
Sigma-Aldrich
4-Hydroxytamoxifen, ≥70% Z isomer (remainder primarily E-isomer)
Pricing and availability is not currently available.
Sigma-Aldrich
IgG from mouse serum, technical grade, ≥80% (SDS-PAGE), buffered aqueous solution
Pricing and availability is not currently available.
Sigma-Aldrich
Dimethyl sulfoxide, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Pricing and availability is not currently available.
Sigma-Aldrich
Anti-ESR1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Pricing and availability is not currently available.
Sigma-Aldrich
Anti-RNA polymerase II Antibody, clone CTD4H8, clone CTD4H8, Upstate®, from mouse
Pricing and availability is not currently available.
Sigma-Aldrich
MISSION® esiRNA, targeting human SALL2
Pricing and availability is not currently available.